fbpx

Search Our Clinical Trials

Conducting trials on a wide range of cancer treatments

The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.

AbbVie, M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Locations

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Abbvie M16-109

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Abbvie M20-178

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis

Locations
Cancer Targeted Myelofibrosis
Request Information
Acerta Pharma ACE-LY-003 (Part 2)

An Open-Label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Indolent Non-Hodgkins Lymphoma
Request Information
ADC Therapeutics ADCT-402-311

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Non-Hodgkins Lymphoma (DLBCL)
Request Information
ALX Oncology Inc., AT148006

A Phase 2/3 Study Of ALX148 In Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Gastric
Request Information
Ambrx, Inc., ACE-Breast-03

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Amgen 20210098

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Locations
Cancer Targeted Gastric
Request Information
Amgen, AMG 552, 20210096

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression

Locations
Cancer Targeted Gastric
Request Information
An Heart / AB-106-G208

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC) Solid Tumors
Request Information
Arcus Biosciences ARC-6

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

Locations

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Prostate Cancer
Request Information
Arcus Biosciences AB154CSP0002 (ARC-7)

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
ASTELLAS, 7517-CL-0101

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Locations
Cancer Targeted Acute Myelogenous Leukemia
Request Information
Astellas 8951-CL-5201

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First-Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Pancreatic Cancer
Request Information
Astrazeneca D3614C00001 (CAPItello-290)

A Phase III Double-Blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Astrazeneca D4194C00008

Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
AstraZeneca, D5086C00001

A Phase III, Open Label, Randomised, 3-Arm, Multi-urothelialCentre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma

Locations
Cancer Targeted Renal Cell Carcinoma
Request Information
BioNTech RNA Pharmaceuticals, BNT122-01

A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Colorectal Cancer
Request Information
BioNTech SE, BNT000-001

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up.

Locations

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Colorectal Cancer
Request Information
Bluestar Genomics IPROCESS-BSG-001-US

Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors (Multiple)
Request Information
BMS CA2097A8

Randomized, Non-Comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer delete ? 2 cm with Safety Run-In, Assessing Nivolumab + Palbociclib + Anastrozole (CheckMate 7A8: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 7A8)

Locations

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
BMS CA2097FL (CheckMate 7FL)

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab Versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients with High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Locations

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Celgene ACE-536-MDS-002 (COMMANDS)

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÏVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted MDS (anemia in MDS patients)
Request Information
Celsion 201-17-201

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Ovarian, Fallopian or 1ry Peritoneal
Request Information
Daiichi Sankyo, DS1062-A-U104

A Phase 1b, Multicenter, 2-Part, Open-Label Study of DS-1062a in Combination with Durvalumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations and Previously Treated with Platinum-based Chemotherapy with or without Prior Immunotherapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Daiichi Sankyo DS1062-A-U301

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung01)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Daiichi Sankyo, DS1062-A-U304

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS 50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-LUNG08)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
DAIICHI SANKYO DS8201-A-U301

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (DS-8201A), an Anti-HER2-Antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with T-DM1

Locations

3300 E. South St.
Suite 304
Long Beach, CA 90805

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Daiichi Sankyo NSABP B-60; DS8201-A-U305

A Phase (3) III, Multicenter, Randomized, A Open-Label, Active-Controlled Study of Trastuzuma Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in subjects with High-Risk Her2-Positive Primary Breast cancer who have Residual Invasive disease in Breast or axillary Lymph nodes following Neoadjuvant Therapy (T-DXd vs T-DM1 in high-risk her2-postive patients with residual invasive breast cancer following neoadjuvant therapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Daiichi Sankyo, PL3397-A-U401

A long-term study to further evaluate the risk of hepatotoxicity associated with TURALIO™ (pexidartinib) treatment.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Observational
Request Information
Dova Pharmaceuticals, AVA-ITP-401

Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Locations

1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745

Cancer Targeted Chronic Immune Thromboytopenia
Request Information
Duality DB-1303-O-1001

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors

Locations

3300 E. South St.
Suite 304
Long Beach, CA 90805

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors
Request Information
eFFECTOR Therapeutics, eFT508-0011

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Eleison EP-GF-301

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Pancreatic Cancer
Request Information
EMD Serono MS200095-0031

A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)

Locations

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Epizyme EZH-302

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo In Combination with Lenalidomide plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Follicular Lymphoma
Request Information
Exact Sciences Thrive – THR-CS-001

Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II

Locations

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Hepatocellular Carcinoma
Request Information
Forma Therapeutics, Inc. 4202-HEM-201

A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Hematology
Request Information
G1 Therapeutics, (G1T28-209)

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Urothelial malignancy
Request Information
GSK, 213400

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
GSK / 213409

An Open-Label, Multicenter, Long-Term Treatment Extension Study In Subjects Who Have Completed A Prior Glaxosmithkline/Tesaro- Sponsored Niraparib Study And Are Judged By The Investigator To Benefit From Continued Treatment With Niraparib.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
GSK 213410

A randomized, open label phase 2/3 study. Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Non small Cell Lung Cancer Who Have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (COSTAR Lung)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Helsinn ANAM-17-20

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Huya Bioscience HBI-8000-303

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Locations
Cancer Targeted Melanoma
Request Information
I-Mab Biopharma US Limited, TJ004309STM103

A Phase 2 Clinical Study Of Tj004309 In Combination With Atezolizumab (Tecentriq®) In Patients With Advanced Or Metastatic Ovarian Cancers And Selected Advanced Solid Tumors

Locations

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Ovarian
Request Information
Incyte Corporation, INCMOR0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory(R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Diffues Large B-Cell Lymphoma (DLBCL)/SLL/Marginal Zone Lymphoma/Follicular
Request Information
Incyte INCMGA 0012-304 (POD1UM304)

A Randomized, Double-Blind, Phase 3 Study of Platinum-Based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Incyte INCMOR0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory(R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
Request Information
InnoCare ICP-CL-00107

A Phase I/II Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Non-Hodgkins Lymphoma (DLBDL)
Request Information
InventisBio Shanghai Limited, InventisBio US, D1553-101

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation.

Locations

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors
Request Information
Ionis ISIS 702843-CS4

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Hematology
Request Information
Janssen 54767414MMY2065

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Multiple Myeloma
Request Information
Janssen MMY2065

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment.

Locations

1707 W. St Marys Rd.
Suite 275
Tucson, AZ 85745

Cancer Targeted Multiple Myeloma
Request Information
Jiangsu Hengrui HR-BLTN-III-NSCLC

A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Kartos KRT-232-101

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Kartos, 232-113

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor Intolerant Myelofibrosis

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Kartos KRT-232-114

An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus associated Kinase

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

4646 Brockton Ave.
Suite 203
Riverside, CA 92506

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Karyopharm Therapeutics KCP-330-024

A Randomized, Double-Blind, Phase 3 Trial Of Maintenance With Selinexor/ Placebo After Combination Chemotherapy For Patients With Advanced Or Recurrent Endometrial Cancer.

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Endometrial
Request Information
Karyopharm Therapeutics Inc., KCP-8602-801

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Acute Myelogenous Leukemia
Request Information
Karyopharm Therapeutics Inc., XPORT-MEL-033

A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination with Pembrolizumab in Recurrent Advanced Melanoma

Locations
Cancer Targeted Melanoma
Request Information
Karyopharm XPORT-DLBCL-030

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Locations

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Non-Hodgkins Lymphoma (DLBCL)
Request Information
Karyopharm, XPORT-MF-034

A Phase 1 / 2 Study to Evaluate Safety and Efficacy of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment Naive Patients with Myelofibrosis

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Karyopharm, XPORT-MF-035

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor versus Treatment of Physician’s Choice in Patients with Previously Treated Myelofibrosis.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

50 Bellefontaine St.
Suite 401
Pasadena, CA 91105

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Myelofibrosis
Request Information
Kura KO-TIP-007

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Head and Neck cancer
Request Information
LOXO-BTK-20019

Phase 3 Open-Label, Randomized Study Of LOXO-305 Versus Investigator Choice of BTK Inhibitor In Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Non-Hodgkins Lymphoma (B-Cell)
Request Information
Loxo Oncology, LOXO-BTK-20023

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313).

Locations
Cancer Targeted Chronic Lymphocytic Leukemia
Request Information
Lutris Pharma. Ltd., L-02-01

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

4646 Brockton Ave.
Suite 203
Riverside, CA 92506

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Colorectal Cancer
Request Information
MEI Pharmaceuticals, ME-401-004

A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

4646 Brockton Ave.
Suite 203
Riverside, CA 92506

Cancer Targeted Non-Hodgkin’s Lymphoma (iNHL)
Request Information
Menarini Ricerche MEN1611-02

Open-Label, Multicenter, Phase IB/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients with PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU, and Anti-EGFR Containing Regimens

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Colorectal Cancer
Request Information
Merck 2140-003

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Locations
Cancer Targeted Non-Hodgkins Lymphoma (B-Cell)
Request Information
Merck 2140-004

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Locations
Cancer Targeted Non-Hodgkins Lymphoma (B-Cell)
Request Information
Merck, MS200095-0031

A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy

Locations

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Mirati 516-005

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

18433 Roscoe Blvd.
Suite 106
Northridge, CA 91325

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

425 Haaland Dr.
Suite 103
Thousand Oaks, CA 91361

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Mirati, 849-007

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Mirati 849-012

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Momenta MOM-M281-006

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted AIHA (Warm)
Request Information
Napo Pharmaceuticals, NP303-102

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted-Cancer Therapies with or without Standard Chemotherapy Regimens.

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

4646 Brockton Ave.
Suite 203
Riverside, CA 92506

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors (Supportive Care)
Request Information
NeoImmunoTech, NIT-119

A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1- expressing, locally advanced or metastatic

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Novocure EF-24 (LUNAR)

LUNAR: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
OncoC4, ONC-392-001

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study

Locations

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Oncternal Therapeutics, CIRM-0001

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

Locations
Cancer Targeted Non-Hodgkins Lymphoma (B-Cell)
Request Information
OnQuality OQL011B002

A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Hand & Foot Skin Reaction
Request Information
Pfizer B8011011

A Phase 1b/2 Open-Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Pfizer C3441037

A Phase 1, Open Label, Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants with Advanced Solid Tumors.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors
Request Information
Pfizer, C3661001

Phase 1/2a dose escalation and expansion study evaluating safety, tolerability, pharmacokinetic, pharmacodynamics and anti-tumor activity of pf-06873600 as a single agent and in combination with endocrine therapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Regeneron, R3918-PNH-2021

A Randomized, Open-Label, Ravulizumab-Controlled Study To Evaluate The Efficacy And Safety Of Pozelimab And Cemdisiran Combination Therapy In Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive Or Have Not Recently Received Complement Inhibitor Therapy.

Locations
Cancer Targeted Hematology
Request Information
Regeneron, R3918-PNH-2022

A Randomized, Open-Label Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with PNH Who are Currently Treated with Eculizumab or Ravulizumab

Locations
Cancer Targeted Hematology
Request Information
Roche/Genentech, WO42633

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate The Efficacy and Safety Of Adjuvant Atezolizumab Or Placebo and Trastuzumab Emtansine For Her2-Positive Breast Cancer at High Risk Of Recurrence Following Preoperative Therapy.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Sanofi Aventis ACT16525

Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, And Pharmacokinetics Of SAR408701 Used In Combination With Ramucirumab In Metastatic, Non-Squamous, Non–Small-Cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy And An Immune Checkpoint Inhibitor.

Locations

1513 S. Grand Ave.
Suite 360
Los Angeles, CA 90015

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer Cohort
Request Information
Sellas SLSG18-301

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Acute Myelogenous Leukemia
Request Information
Shanghai Haihe SCC244-108

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

Locations

900 S. Main St.
Suite 204
Corona, CA 92882

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer - NSCLC
Request Information
Spectrum SPI-BEL-107

An Open-label, Nonrandomized, Phase 1 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of Belinostat in Combination with Atazanavir in Patients with Advanced Relapsed/Refractory Solid Tumors or Hematological Malignancies

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors
Request Information
Sun Pharma CLR_15_03 PART C

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Locations

1801 W Romneya Dr.
Suite 103
Anaheim, CA 92801

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

101 E. Beverly Blvd.
Suite 200
Montebello, CA 90640

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

21605 Hawthorne Blvd.
Suite 200
Torrance, CA 90503

1250 S. Sunset Ave.
Suite 101
West Covina, CA 91790

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted CML / ALL
Request Information
Suzhou Zanrong (Zion) ZN-A-1041-101

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Veru Inc., V3002401

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining ≥40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor (Arimidex, Femera), Fulvestrant and CDK 4/6 inhibitor

Locations
Cancer Targeted Breast Cancer
Request Information
Vifor (International) Inc., VIT-2763-THAL-203

A Phase 2b, double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent -thalassemia.

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Hematology
Request Information
Viracta Therapeutics, VT3996-202

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+)

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
Request Information
Viracta Therapeutics, VT3996-301

An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Solid Tumors Hematology
Request Information
Xbiotech, 2020-PT049

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Pancreatic Cancer
Request Information
Yingli Pharma., YL-15293-001

A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects with Advanced Solid Tumors with a KRAS G12C Mutation

Locations
Cancer Targeted Solid Tumors
Request Information
Zenshine, ZX-101A-101

A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients with Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Locations

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Chronic Lymphocytic Leukemia
Request Information
Zhejiang Teruisi Pharma., TRS00303001

A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety between TRS003 and China-approved Bevacizumab Administered in Combination with Paclitaxel-Carboplatin in Subjects with Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Locations

11480 Brookshire Ave.
Suite 309
Downey, CA 90241

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

3628 E. Imperial Hwy.
Suite 401
Lynwood, CA 90262

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Lung Cancer (NSCLC)
Request Information
Zion ZN-A-1041-101

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors.

Locations

1701 E. Cesar Chavez Ave.
Suite 535
Los Angeles, CA 90033

1510 S. Central Ave.
Suite 240
Glendale, CA 91204

3300 E. South St.
Suite 304
Long Beach, CA 90805

999 N. Tustin Ave
Suite 212
Santa Ana, CA 92705

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted Breast Cancer
Request Information
Zymeworks ZWI-ZW25-203

A Phase 2b, Open-Label, Single-Arm Study of ZW25 Monotherapy in Subjects with Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Locations

3300 E. South St.
Suite 304
Long Beach, CA 90805

8135 S. Painter Ave.
Suite 103
Whittier, CA 90602

Cancer Targeted CholangioCarcinoma & Gall Bladder Cancer
Request Information
Skip to content